Versiti - Technology Transfer Office | Versiti Blood Research Institute
 

Office of Research Innovation & Technology Transfer

Supporting advances in technology across Versiti.

Office of Research Innovation & Technology Transfer (RITT)


The Office of Research Innovation & Technology Transfer (RITT) at Versiti Blood Research Institute protects technological advances and medical resources across Versiti, transforming them into discoveries that save and improve patient lives. We accomplish this research translation and product development efforts into new medical diagnostic tools for patients; new medical tools for physicians; new tools used for ongoing basic discovery efforts; and new and improved delivery of therapeutics and knowledge for physicians, scientists and people worldwide.

 

Services

Tech transfer staff provide patent management, licensing and contract negotiation services to scientists and Versiti partners.

Available Technologies

Versiti has a number of patented technologies currently available for licensing. We also have collections of antibodies, transgenic mice and other scientific materials available to the research community.

 
 

Education

Versiti, in collaboration with regional tech transfer offices and other organizations in southeastern Wisconsin, has developed a series of web-based video learning modules designed to introduce researchers to the technology transfer process.

Learn more.

Cell Therapy

ADApted Chimeric Antigen Receptor controls inflammation

A safety improvement to existing Chimeric Antigen Receptor (CAR) therapy that controls cytokine release syndrome. Short peptides are cloned into existing CAR constructs.

CAR-T cells ReACT to solid tumors

Genetically engineered T cells from a patient's own tumor combined with chimeric antigen receptor and vaccine technology offers a lasting cure for solid tumors.

Diagnostic

Platelet Typing

Improved DNA-based diagnostic assay to identify platelet-specific alloantigens involved in immune thrombocytopenias or platelet mismatch of mom and fetus during pregnancy.

Von Willebrand Disease Screening Assay

Improved and simplified diagnostic assay for von Willebrand Disease (VWD) screening. No need for ristocetin, aggregometer, or platelet reagents, reducing assay costs and false positives, while improving reproducibility.

Drug

Lipid-Lowering tPA-K2 to Reduce Atherogenic Lipoproteins to Lower Residual Cardiovascular Risk

The novel link between the intracellular function of tissue-type plasminogen activator (tPA) and Apolipoprotein B (apoB) in hepatocytes shows great promise for developing a drug to lower all bad atherogenic lipoproteins by tPA fragments and reduce cardiovascular risk.

Reagent

Designer Platelets

CRISPR customized platelets or cells with specific alloantigens for use in blood typing, diagnostics or platelet transfusions.

Versiti Blood Research Institute
8733 W. Watertown Plank Rd.
Milwaukee, WI 53226

John Mabry, PhD
Director
Hanna Weber, MS
Technology Transfer Associate
Material Transfer Agreements
 
Accreditations & Licenses
Versiti and its affiliates hold numerous accreditations and licenses, listed here for each Versiti affiliate.
 
Scientific Programs
Scientific research and training are important parts of Versiti’s mission. Our research programs involve basic and clinical scientists at Versiti Blood Research Institute.
 
Shared Core Facilities
Versiti Blood Research Institute’s Shared Resources department includes core laboratories, shared equipment and specialized research services.
 
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.